Drug Patents owned by Myovant Sciences

1. List of Myfembree drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7300935 MYOVANT SCIENCES Thienopyrimidine compounds and use thereof
Jan, 2024

(11 months from now)

US8058280 MYOVANT SCIENCES Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof
Jan, 2024

(11 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9346822 MYOVANT SCIENCES Thienopyrimidine compounds and use thereof
Feb, 2024

(1 year, 7 days from now)

US11033551 MYOVANT SCIENCES Methods of treating uterine fibroids
Sep, 2037

(14 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 18, 2025
New Product (NP) May 26, 2024
New Indication (I) Aug 5, 2025

Drugs and Companies using ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX ingredient

NCE-1 date: December, 2024

Market Authorisation Date: 26 May, 2021

Treatment: Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women

Dosage: TABLET;ORAL

More Information on Dosage

MYFEMBREE family patents

20

United States

8

Japan

8

European Union

5

Australia

4

Israel

4

China

4

Canada

3

Morocco

3

Brazil

3

Mexico

3

Argentina

3

EA

3

New Zealand

2

Poland

2

Lithuania

2

Spain

2

Slovenia

2

Hungary

2

Portugal

2

Norway

2

Denmark

1

Hong Kong

1

RS

1

Korea, Republic of

1

Netherlands

1

Moldova, Republic of

1

Cyprus

1

South Africa

1

Colombia

1

Russia

1

Croatia

1

Taiwan, Province of China

2. List of Orgovyx drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8058280 MYOVANT SCIENCES Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof
Jan, 2024

(11 months from now)

US7300935 MYOVANT SCIENCES Thienopyrimidine compounds and use thereof
Jan, 2024

(11 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8735401 MYOVANT SCIENCES Thienopyrimidine compounds and use thereof
Feb, 2024

(11 months from now)

US10350170 MYOVANT SCIENCES Solid preparation
Feb, 2036

(13 years from now)

US10786501 MYOVANT SCIENCES Treatment of prostate cancer
Sep, 2037

(14 years from now)

US10449191 MYOVANT SCIENCES Treatment of prostate cancer
Sep, 2037

(14 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 18, 2025

Drugs and Companies using RELUGOLIX ingredient

NCE-1 date: December, 2024

Market Authorisation Date: 18 December, 2020

Treatment: Treatment of adult patients with advanced prostate cancer that is sex-hormone-dependent; Treatment of adult patients with advanced prostate cancer

Dosage: TABLET;ORAL

More Information on Dosage

ORGOVYX family patents

23

United States

11

Japan

9

European Union

6

Australia

5

Israel

5

China

5

Canada

4

Brazil

4

Mexico

4

New Zealand

3

Morocco

3

Argentina

3

EA

2

Poland

2

Lithuania

2

Spain

2

Slovenia

2

Hungary

2

Portugal

2

Norway

2

Taiwan, Province of China

2

Denmark

1

Hong Kong

1

RS

1

Korea, Republic of

1

Malaysia

1

Netherlands

1

Moldova, Republic of

1

Cyprus

1

South Africa

1

Colombia

1

Russia

1

Croatia

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic